Clinical trials: Tocilizumab, open to volunteers
Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss
Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer
This is a Phase 1b/2, multi-site, single-arm, open-label, non-randomized study looking at whether adding tocilizumab to standard treatment for metastatic Non-Small Cell Lung Cancer (NSCLC) is safe, possible, and effective.
- Conditions
- Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss, Elevated Inflammatory Markers
- Trial name
- TOCI (NCT07889232)
- Testing
- Tocilizumab, Pembrolizumab, Platinum-Doublet Chemotherapy
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- VA Office of Research and Development
Chronic Lymphocytic Leukemia, Richter's Transformation
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into…
- Trial name
- NCT06043674
- Testing
- Glofitamab, Obinutuzumab, Polatuzumab Vedotin
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- Christine Ryan
Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
This study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential…
- Trial name
- SMART-JIA (NCT06654882)
- Testing
- TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab
- Where
- 7 sites in United States, Germany and 2 more
- Volunteers
- 400 people
- Sponsor
- Duke University
Multiple Myeloma
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab…
- Trial name
- CAMMA 1 (NCT04910568)
- Testing
- Cevostamab, Tocilizumab, Pomalidomide
- Where
- 34 sites in United States, Australia and 11 more
- Volunteers
- 186 people
- Sponsor
- Genentech, Inc.
Sepsis
Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial
PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments.
- Trial name
- PALETTE (NCT06381661)
- Testing
- Tocilizumab, Baricitinib, Anakinra
- Where
- 19 sites in France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
B-cell Acute Lymphoblastic Leukemia
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Researchers are looking for new ways to treat people with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) that is CD19 positive using a medicine called MK-1045.
- Trial name
- NCT07570173
- Testing
- MK-1045, Blinatumomab, Acetaminophen
- Where
- 27 sites in Canada, Denmark and 8 more
- Volunteers
- 340 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma
Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) in patients with multiple myeloma (MM) who have received one to four prior lines of therapy…
- Trial name
- NCT07825064
- Testing
- Cevostamab, Pomalidomide, Dexamethasone
- Where
- 2 sites in Germany
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Cholangiocarcinoma, Colorectal Cancer
TCR1188-ABC Cells in KRAS-mutated Cancers
This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1188-ABC cells in patients with KRAS-mutated cancers.
- Conditions
- Cholangiocarcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT07594067
- Testing
- TCR1188-ABC cells, Fludarabine + Cyclophosphamide combination, Tocilizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pennsylvania
Ischemic Stroke
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke
This is an investigator-initiated phase III clinical trial employing a randomized, double-blind, placebo-controlled design. The primary objective of this study is to investigate the efficacy and safety of an interleukin-6…
- Trial name
- IRIS-3 (NCT07509645)
- Testing
- Tocilizumab
- Where
- 30 sites in China
- Volunteers
- 348 people
- Sponsor
- Capital Medical University
Ovarian Neoplasms, Endometrial Neoplasms
A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001)
Researchers are looking for new ways to treat advanced and recurrent endometrial cancer (EC) and ovarian cancer (OC). Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery.
- Trial name
- NCT07870278
- Testing
- MK-6255, CD8 PET Tracer, Acetaminophen
- Volunteers
- 80 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Ischemic Stroke
Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATE
The goal of this phase II, placebo-controlled intervention study is to investigate whether tocilizumab, an interleukin-6 (IL-6) receptor inhibitor, may have a neuroprotective effect by reducing infarct growth in adults with acute…
- Trial name
- Illuminate (NCT07870681)
- Testing
- Tociliuzumab
- Where
- 6 sites in Denmark, Norway
- Volunteers
- 156 people
- Sponsor
- Oslo University Hospital
Metastatic Breast Cancer
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages.
- Trial name
- Morpheus-panBC (NCT03424005)
- Testing
- Capecitabine, Atezolizumab, Ipatasertib
- Where
- 55 sites in United States, Australia and 7 more
- Volunteers
- 1,132 people
- Sponsor
- Hoffmann-La Roche
Acute Hypoxemic Respiratory Failure
Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study
Acute hypoxemic respiratory failure (AHRF) happens when the lungs are unable to absorb enough oxygen. The bloodstream is deprived of oxygen which can eventually lead to more severe conditions like multi-organ failure (MOF) and…
- Trial name
- IDENTIFY (NCT07334379)
- Testing
- Tocilizumab (Actemra®), Dexamethasone
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Lorenzo delSorbo
Lung Transplant
Tocilizumab in Lung Transplantation
This is a trial in which 100 primary lung transplant recipients will be randomized (1:1) to receive either Tocilizumab (six doses over 20 weeks) plus standard triple maintenance immunosuppression or placebo (sterile normal…
- Trial name
- ALL IN LUNG (NCT06033196)
- Testing
- Tocilizumab
- Where
- 21 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
Researchers are looking for new ways to treat people with B-cell cancers. In this trial, researchers will look at chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
- Conditions
- Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic Malignancies
- Trial name
- NCT07709000
- Testing
- MK-1045, Acetaminophen (or similar antipyretic), Diphenhydramine (or similar antihistamine)
- Where
- 5 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab (Lunsumio) monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small…
- Trial name
- NCT05091424
- Testing
- Mosunetuzumab, Tocilizumab, Venetoclax
- Where
- 31 sites in United States, Australia and 8 more
- Volunteers
- 332 people
- Sponsor
- Hoffmann-La Roche
Mature B-Cell Non-Hodgkin Lymphoma
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric…
- Trial name
- iMATRIX GLO (NCT05533775)
- Testing
- Obinutuzumab, Glofitamab, Rituximab
- Where
- 30 sites in United States, Australia and 11 more
- Volunteers
- 65 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
CO43923 is a platform study that will evaluate the safety, efficacy, and pharmacokinetics (PK) of multiple treatment combinations, as monotherapy or in combination, in participants with multiple myeloma (MM).
- Trial name
- PLYCOM (NCT05583617)
- Testing
- Cevostamab, Lenalidomide, Tocilizumab
- Where
- 16 sites in Australia, France and 4 more
- Volunteers
- 200 people
- Sponsor
- Hoffmann-La Roche
Relapsed or Refractory Multiple Myeloma
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment.
- Trial name
- NCT05927571
- Testing
- Cevostamab, Elranatamab, Tocilizumab
- Where
- 14 sites in Australia, Israel and 1 more
- Volunteers
- 120 people
- Sponsor
- Genentech, Inc.
Lymphoma
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed…
- Trial name
- GLOBRYTE (NCT06084936)
- Testing
- Obinutuzumab, Glofitamab, Rituximab
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 182 people
- Sponsor
- Hoffmann-La Roche